Industry Veteran Brett Scott Joins North American Scientific as Chief Financial Officer

CHATSWORTH, Calif.--(Business Wire)--
North American Scientific (NASDAQ:NASM) announced today that it
has appointed Brett L. Scott, CPA to the position of Chief Financial
Officer. Mr. Scott will join the NASM Senior Team effective August 11,
2008, and will report directly to John Rush, President and CEO.

"We are pleased to attract someone with the level of experience
and success that Brett brings to the organization" said Mr. Rush. "He
will be an integral part of the senior management team and an
invaluable asset in the strategic planning process. Brett's hiring
marks the completion of the executive team build out we started a year
ago."

Mr. Scott joins North American Scientific from his role as CFO at
Alsius Corporation, a publicly traded medical device company focused
on temperature control of patients in the critical care arena. During
his tenure at Alsius, Mr. Scott played an integral part in the merger
of Alsius and Ithaka Corporation (A Specified Purpose Acquisition
Company (SPAC)), and was responsible for the implementation of SOX,
SEC reporting and compliance, and investor relations. Mr. Scott has
also held the position of Chief Financial Officer with the following
companies: Irvine Biomedical, a medical device company which was
acquired by St. Jude Medical; Pain Concepts, a medical device company
who's flagship product was acquired by Stryker Medical; Cardiac
Science, a publicly traded medical device company who merged with
Quinton Cardiology Systems; and finally, Neuro Navigational
Corporation, a publicly traded medical device company which was sold
to Ballard Medical. Mr. Scott is a certified public accountant and
received his BS from the University of Southern California.

About North American Scientific

North American Scientific is a medical device company focused on
developing products which deliver local controlled radiation therapy
for cancer. Its innovative products allow patients to be treated
effectively with a shortened course of treatment and reduced side
effects. Current products include the Prospera(R) Iodine and Palladium
seeds and SurTRAK(TM) needles and strands used primarily in the
treatment of prostate cancer. Additionally, the Company has been
gaining clinical experience with its ClearPath(TM) multi-channel
catheter device for local radiation delivery in the breast cancer
patient. The ClearPath family of products are the only such devices
approved for both high dose and continuous release, or low dose, local
radiation treatments for breast cancer. The devices are designed to
provide flexible, precise dose customization and unparalleled patient
comfort in a shortened, effective course of treatment. Please visit
www.nasmedical.com for more information.

North American Scientific
John Rush, CEO
IR@nasmedical.com
(818) 734-8600

Copyright Business Wire 2008